CURI Stock CuriosityStream (CURI, $4.77) Aroon Indicator entered a Downtrend on July 25, 2025.

GET DAILY SIGNALS

Get AI intraday signals

CURI - CuriosityStream

Aroon signal

View

Odds of DOWN Trend

Price: $4.77

Daily change: +$0.22 (+4.84%)

Daily volume: 428K

Capitalization: $275.3M

Industry: Broadcasting

CURI's Stochastic Oscillator is remaining in overbought zone for 1 day

Expect a price pull-back in the near future.

Technical Analysis (Indicators)

Bearish Trend Analysis

CURI moved below its 50-day moving average on July 02, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CURI crossed bearishly below the 50-day moving average on July 09, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CURI entered a downward trend on July 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 25, 2025. You may want to consider a long position or call options on CURI as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CURI just turned positive on July 23, 2025. Looking at past instances where CURI's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CURI advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CURI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CURI's P/B Ratio (4.737) is slightly higher than the industry average of (1.436). CURI has a moderately low P/E Ratio (0.000) as compared to the industry average of (12.140). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.774). Dividend Yield (0.036) settles around the average of (0.040) among similar stocks. P/S Ratio (4.878) is also within normal values, averaging (5.441).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CURI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.